Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.

<h4>Background</h4>There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure.<h4>Methodology/principal finding...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Kuenzli, Heiner C Bucher, Inder Anand, Gregory Arutiunov, Leo C Kum, Robert McKelvie, Rizwan Afzal, Michel White, Alain J Nordmann
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2010
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8193889c7c6b4f7c9048f7ccd85da341
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8193889c7c6b4f7c9048f7ccd85da341
record_format	dspace
spelling	oai:doaj.org-article:8193889c7c6b4f7c9048f7ccd85da3412021-12-02T20:11:53ZMeta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.1932-620310.1371/journal.pone.0009946https://doaj.org/article/8193889c7c6b4f7c9048f7ccd85da3412010-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20376345/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure.<h4>Methodology/principal findings</h4>Two independent reviewers searched and abstracted randomized controlled trials of ARBs and ACE inhibitors compared to ACE inhibitor therapy alone in patients with heart failure reporting mortality and hospitalizations having a follow-up of at least 6 months identified by a systematic literature search. Eight trials including a total of 18,061 patients fulfilled our inclusion criteria. There was no difference between patients treated with combination therapy and ACE inhibitor therapy alone for overall mortality, hospitalization for any reason, fatal or nonfatal MI. Combination therapy was, however, associated with fewer hospital admissions for heart failure (RR 0.81, 95%CI 0.72-0.91), although there was significant heterogeneity across trials (p-value for heterogeneity = 0.04; I(2) = 57% [95%CI 0-83%]). Patients treated with combination therapy had a higher risk of worsening renal function and symptomatic hypotension, and their trial medications were more often permanently discontinued. Lack of individual patient data precluded the analysis of time-to-event data and identification of subgroups which potentially benefit more from combination therapy such as younger patients with preserved renal function and thus at lower risk to experience worsening renal function or hyperkalemia.<h4>Conclusions/significance</h4>Combination therapy with ARBs and ACE inhibitors reduces admissions for heart failure in patients with congestive heart failure when compared to ACE inhibitor therapy alone, but does not reduce overall mortality or all-cause hospitalization and is associated with more adverse events. Thus, based on current evidence, combination therapy with ARBs and ACE inhibitors may be reserved for patients who remain symptomatic on therapy with ACE inhibitors under strict monitoring for any signs of worsening renal function and/or symptomatic hypotension.Andrea KuenzliHeiner C BucherInder AnandGregory ArutiunovLeo C KumRobert McKelvieRizwan AfzalMichel WhiteAlain J NordmannPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 5, Iss 4, p e9946 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andrea Kuenzli Heiner C Bucher Inder Anand Gregory Arutiunov Leo C Kum Robert McKelvie Rizwan Afzal Michel White Alain J Nordmann Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
description	<h4>Background</h4>There is insufficient evidence whether the benefit of adding angiotensin II receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the increased risk of adverse effects in patients with heart failure.<h4>Methodology/principal findings</h4>Two independent reviewers searched and abstracted randomized controlled trials of ARBs and ACE inhibitors compared to ACE inhibitor therapy alone in patients with heart failure reporting mortality and hospitalizations having a follow-up of at least 6 months identified by a systematic literature search. Eight trials including a total of 18,061 patients fulfilled our inclusion criteria. There was no difference between patients treated with combination therapy and ACE inhibitor therapy alone for overall mortality, hospitalization for any reason, fatal or nonfatal MI. Combination therapy was, however, associated with fewer hospital admissions for heart failure (RR 0.81, 95%CI 0.72-0.91), although there was significant heterogeneity across trials (p-value for heterogeneity = 0.04; I(2) = 57% [95%CI 0-83%]). Patients treated with combination therapy had a higher risk of worsening renal function and symptomatic hypotension, and their trial medications were more often permanently discontinued. Lack of individual patient data precluded the analysis of time-to-event data and identification of subgroups which potentially benefit more from combination therapy such as younger patients with preserved renal function and thus at lower risk to experience worsening renal function or hyperkalemia.<h4>Conclusions/significance</h4>Combination therapy with ARBs and ACE inhibitors reduces admissions for heart failure in patients with congestive heart failure when compared to ACE inhibitor therapy alone, but does not reduce overall mortality or all-cause hospitalization and is associated with more adverse events. Thus, based on current evidence, combination therapy with ARBs and ACE inhibitors may be reserved for patients who remain symptomatic on therapy with ACE inhibitors under strict monitoring for any signs of worsening renal function and/or symptomatic hypotension.
format	article
author	Andrea Kuenzli Heiner C Bucher Inder Anand Gregory Arutiunov Leo C Kum Robert McKelvie Rizwan Afzal Michel White Alain J Nordmann
author_facet	Andrea Kuenzli Heiner C Bucher Inder Anand Gregory Arutiunov Leo C Kum Robert McKelvie Rizwan Afzal Michel White Alain J Nordmann
author_sort	Andrea Kuenzli
title	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
title_short	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
title_full	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
title_fullStr	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
title_full_unstemmed	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.
title_sort	meta-analysis of combined therapy with angiotensin receptor antagonists versus ace inhibitors alone in patients with heart failure.
publisher	Public Library of Science (PLoS)
publishDate	2010
url	https://doaj.org/article/8193889c7c6b4f7c9048f7ccd85da341
work_keys_str_mv	AT andreakuenzli metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT heinercbucher metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT inderanand metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT gregoryarutiunov metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT leockum metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT robertmckelvie metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT rizwanafzal metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT michelwhite metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure AT alainjnordmann metaanalysisofcombinedtherapywithangiotensinreceptorantagonistsversusaceinhibitorsaloneinpatientswithheartfailure
_version_	1718374895050555392

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.

Ejemplares similares